Preclinical Establishment of a Divalent Vaccine against SARS-CoV-2

Preclinical Establishment of a Divalent Vaccine against SARS-CoV-2

First-generation vaccines against SARS-CoV-2 do not provide adequate immune protection. Therefore, we engineered a divalent gene construct combining the receptor-binding domain (RBD) of the spike protein and the immunodominant region of the viral nucleocapsid. This fusion protein was produced in eit...

Full description

Bibliographic Details
Main Authors: Zsofia Hevesi, Daniela Anna Gerges, Sebastian Kapps, Raimundo Freire, Sophie Schmidt, Daniela D. Pollak, Klaus Schmetterer, Tobias Frey, Rita Lang, Wolfgang Winnicki, Alice Schmidt, Tibor Harkany, Ludwig Wagner
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Vaccines
Subjects:
receptor-binding domain
nucleocapsid
bivalent vaccine
neuroinflammation
Online Access:https://www.mdpi.com/2076-393X/10/4/516

Internet

https://www.mdpi.com/2076-393X/10/4/516

Similar Items